Rosalind Advisors Inc. Buys 740,355 Shares of OptiNose, Inc. (NASDAQ:OPTN)

Rosalind Advisors Inc. raised its stake in OptiNose, Inc. (NASDAQ:OPTN) by 9.8% during the third quarter, Holdings Channel reports. The fund owned 8,287,503 shares of the company’s stock after buying an additional 740,355 shares during the period. OptiNose makes up approximately 3.5% of Rosalind Advisors Inc.’s portfolio, making the stock its 12th largest position. Rosalind Advisors Inc. owned 0.05% of OptiNose worth $5,553,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of OPTN. Vanguard Group Inc. lifted its stake in OptiNose by 1.5% in the first quarter. Vanguard Group Inc. now owns 4,242,610 shares of the company’s stock valued at $6,194,000 after purchasing an additional 62,906 shares during the last quarter. Massachusetts Financial Services Co. MA grew its position in shares of OptiNose by 2.9% in the second quarter. Massachusetts Financial Services Co. MA now owns 2,920,309 shares of the company’s stock valued at $3,037,000 after purchasing an additional 81,233 shares in the last quarter. XTX Topco Ltd bought a new stake in shares of OptiNose during the 2nd quarter valued at $88,000. Squarepoint Ops LLC lifted its holdings in OptiNose by 173.7% during the 2nd quarter. Squarepoint Ops LLC now owns 171,610 shares of the company’s stock worth $178,000 after purchasing an additional 108,903 shares in the last quarter. Finally, Rice Hall James & Associates LLC boosted its stake in OptiNose by 15.4% in the 3rd quarter. Rice Hall James & Associates LLC now owns 1,140,626 shares of the company’s stock worth $764,000 after purchasing an additional 152,435 shares during the period. 85.60% of the stock is owned by institutional investors.

OptiNose Price Performance

OPTN stock opened at $0.67 on Wednesday. The stock has a 50-day simple moving average of $0.80 and a two-hundred day simple moving average of $0.97. OptiNose, Inc. has a twelve month low of $0.65 and a twelve month high of $2.10. The firm has a market capitalization of $101.04 million, a PE ratio of -1.86 and a beta of -0.07.

OptiNose (NASDAQ:OPTN) last posted its earnings results on Thursday, August 8th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.01. The firm had revenue of $20.49 million during the quarter, compared to analysts’ expectations of $20.81 million. On average, equities research analysts anticipate that OptiNose, Inc. will post -0.22 EPS for the current fiscal year.

About OptiNose

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.